RecruitingNCT07636252

EX VIVO DRUG RESPONSE PROFILING AND OUTCOME PREDICTION IN LUNG ADENOCARCINOMA


Sponsor

Sheba Medical Center

Enrollment

400 participants

Start Date

Jun 14, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing.
  • Patient's written informed consent present.
  • Ability to understand the nature of the trial and the trial related procedures and to comply with them.

Exclusion Criteria1

  • negative cytology for malignancy in the last 6 months

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNon-Interventional Study

Non-Interventional Study, patients go through pleural drainage due to shortness of breath


Locations(1)

Sheba Medical Center

Ramat Gan, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07636252


Related Trials